




CORTELLIS 交易情报 快速参考指南



专业信息引领
中国药企创新与国际化

什么是Cortellis交易情报?

Cortellis 交易情报是一个基于 Cortellis 平台的独立优质的交易数据库。该数据库提供交易情报和见解，帮助您比较交易条目，评估交易价值，寻找潜在的合作伙伴，促成最佳交易。交易情报的大部分数据、特性和功能来源于原产品 Recap，在此基础上还提供了更多的数据和功能，例如全新的搜索模式：Cortellis 的主要搜索策略是“先搜索再筛选”，而原 Recap 的模式是“先筛选再搜索”。

检索示例

检索示例将以检索类风湿性关节炎领域已经披露财务信息的交易为例。您将会看到一份交易报告，包括 (a) 与交易相关的药物信息；(b) 一份包含具体交易事件的交易综述；和 (c) 与财务信息相关的各类表格。您将会看到示例中同时利用了“先搜索再筛选”的策略（快速查询模式）和与 Recap 相似的“先筛选再搜索”（高级查询模式）的策略。

快速检索

1. 访问 Cortellis 登录页面，输入您的用户名和密码，点击 **Log in** 登录。

Cortellis

Clarivate Analytics

Home News System Requirements Training About Us Site Search

Make target identification failure a thing of the past
Learn more
Clarivate Analytics

Cortellis Regulatory Intelligence for Medical Devices and IVDs
Available Now
Clarivate Analytics

Cortellis Deals Intelligence
Find and compare life sciences deals to enable effective

Cortellis
Powering Life Sciences Innovation

NEW SENDER ADDRESS FOR CORTELLIS ALERTS

The sender e-mail address for Cortellis alerts (Cortellis "Save and Alert" alerts; Regulatory Intelligence Weekly Alerts; Regulatory Intelligence AdComm alerts) will change from cortellis.alerts@thomsonreuters.com to cortellis.alerts@clarivate.com, with the display name "Cortellis Alerts". This will be effective for alerts received starting Friday, September 8. Note that following the change, you may need to update your e-mail rules and, if you do not receive expected alerts, please check your spam folder.

Log-in to your account

Username:
Password:
 Remember me **Log in**


[Forgotten your password?](#)
[Can't access your account?](#)

or


Sign in with SSO

Bookmark this Page

2. 您会进入到 Cortellis 主页。搜索栏位于主页上方。



3. 您可输入多种类型的关键字进行检索，包括适应症、公司名、药品名等。例如当键入“rheumatoid arthritis (类风湿性关节炎)”时，系统会出现自动一些匹配项，选择“rheumatoid arthritis”后，点击 **SEARCH** 查询。



4. 进入查询结果列表，点击左侧“Report Type”中的“Deals”，获取相关的交易报告结果，同时可以看到查询结果的数量。此时页面中显示了众多信息，您可进行许多操作，例如：


点击 A 处：打开一个交易报告；

点击 B 处：使用“Filters”筛选功能对结果进行过滤，得到您最感兴趣的信息；


点击 C 处：将数据导出供离线使用并可以分享给同事。导出的 Excel 格式的文件中包含了大量的信息和图表，便于您进一步分析交易中的财务信息；

点击 D 处：创建 email 提醒功能，系统会自动提醒搜索内容中最近更新的信息。


点击各处的 Filters 功能，均可对查询结果进行相应的筛选。



5. 使用 Filter 功能时会出现一个新的窗口，在左侧向下滚动鼠标选择“**Indications**（适应症）”，即可对与类风湿性关节炎相关的交易进行筛选。点击“**Hierarchical List**（分级列表）”，这里提供了治疗领域和相关适应症的分层，方便您对各个子类进行筛选。这时，可在左上角的搜索栏中输入 **rheumatoid arthritis** 然后点击 **Look up**，与该治疗领域相关的子类将在列表中变为高亮显示，继续点击‘+’可以查看下一级列表内容。此时可以看到与 Rheumatoid arthritis 相关的子条目已经被自动选定了。



6. 点击 **Finance Disclosed** 筛选项，选择 **Yes** 并点击 **Apply**，筛选已披露财务信息的交易。



7. 此时查询列表将被更新。检索结果的数量和所使用的筛选条件也会显示。点击 **Deal Start Date** 可以使交易按照时间排序。使用表格下方的滚动条可以查看更多列的信息。另外，**Order Columns** 功能可以自定义您的表格列显示顺序；**Results per page** 功能可以更改每页显示的结果数量。

76 results found for "'rheumatoid arthritis'" with filter(s) applied: Yes, Rheumatoid arthritis

Results Per page: 10 Sort by: Deal Start Date Most Recent Order Columns View

Deal Title	Principal Company	Partner Company	Deal Type	Deal Asset Type	Deal Transaction Type
Dong-A to develop and commercialize Tobira's cenicriviroc in the Republic of Korea for all therapeutic indications	Tobira Therapeutics Inc	Dong-A ST Co Ltd	Drug - Development/Commercialization License	Product(s) only	Basic License (Licensee takes over)
Bristol-Myers Squibb acquires Padlock Therapeutics	Padlock Therapeutics Inc	Bristol-Myers Squibb Co	Company - M&A (in whole or part)	Company	Acquisition - Full (100%)
Arthritis Foundation to award Vanderbilt University funding for discovering extracellular	Vanderbilt University	Arthritis Foundation	Drug - Funding	Capital(Grants/Loans/Equity Inv./ Royalty buyouts)	Grant

8. 点击交易标题的超链接即可打开交易报告。例如打开图中的 Galapagos NV 和 Gilead Sciences 公司的交易。

Gilead Sciences to develop and commercialize Galapagos' figotinib against rheumatoid arthritis and inflammatory disease worldwide	Galapagos NV	Gilead Sciences Inc	Drug - Development/Commercialization License	Product(s) only	Co-Development/Co-Development Option (Share responsibilities and costs) ; Co-Promotion/Co-Promotion Option (One party books sales/ shared promotion)
Sekisui Chemical to acquire EIDIA	Eidia Co Ltd	Sekisui Chemical Co Ltd	Company - M&A (in whole or part)	Company	Acquisition - Full (100%)

9. 这是一个典型的 Deal Report (交易报告)。通过左侧的标签可以查看相应的信息。**Snapshot** 标签内显示了该交易的最主要信息, 包括交易双方的公司名, 交易类型, 涉及领域, 总交易额, 适应症和相关技术。

Deal Report	
<p>Back Forward Alert Export</p> <p>Gilead Sciences to develop and commercialize Galapagos' filgotinib against rheumatoid arthritis and inflammatory disease worldwide</p>	
Snapshot	<p>Highlight Search Terms & Synonyms < Previous Next ></p> <p>SNAPSHOT</p> <p>Deal Title Gilead Sciences to develop and commercialize Galapagos' filgotinib against rheumatoid arthritis and inflammatory disease worldwide</p> <p>Principal Company Galapagos NV (Belgium)</p> <p>Partner Company Gilead Sciences Inc (US)</p> <p>Deal Type Drug - Development/Commercialization License</p> <p>Deal Asset Type Product(s) only</p> <p>Deal Transaction Type Co-Development/Co-Development Option (Shared responsibilities and costs); Co-Promotion/Co-Promotion Option (One party books sales/ shared promotion)</p> <p>Deal Status Active</p> <p>Territories World</p> <p>Total projected value (Current-USD M) 2075.00</p> <p>Total projected value (At Signing-USD M) 2075.00</p> <p>Total Paid (USD M) 725.00</p> <p>Indications Colitis, Crohns disease, Rheumatoid arthritis</p> <p>Target-based Actions Jak1 tyrosine kinase inhibitor</p> <p>Other Actions Anti-inflammatory</p> <p>Technologies Small molecule therapeutic(Primary), Capsule formulation, Oral formulation</p>
Drugs	
Patents	
Contract	
Events	
Financial	
Mergers & Acquisition	
Sources	

10. **Drugs** 标签中显示了交易涉及的药物信息、目前的最高开发阶段和交易开始的日期。点击 **Current Development Status** 可以查看该药物的各个适应症在所有相关国家的开发阶段。这一新功能是 Cortellis 数据库特有的, 而不在原有的 Recap 功能中。此外, 如果该交易涉及专利信息或合同信息, 点击左侧的相应标签即可查看。

Gilead Sciences to develop and commercialize Galapagos' filgotinib against rheumatoid arthritis and inflammatory disease worldwide																															
Snapshot	<p>Highlight Search Terms & Synonyms < Previous Next ></p> <p>DRUGS</p> <p>filgotinib</p> <p>Drug Name filgotinib</p> <p>Target-based Actions Jak 1 tyrosine kinase inhibitor</p> <p>Other Actions Anti-inflammatory</p> <p>Technologies Capsule formulation ; Oral formulation ; Small molecule therapeutic ; Tablet formulation</p> <p>Highest Phase (Deal Start Date) Phase 2 Clinical</p> <p>Highest Phase (Current) Phase 3 Clinical</p> <p>Current Development Status</p> <table border="1"> <thead> <tr> <th>Company</th> <th>Indication</th> <th>Country</th> <th>Development Status</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>Galapagos NV</td> <td>Rheumatoid arthritis</td> <td>Europe</td> <td>Phase 3 Clinical</td> <td>31-Jul-2016</td> </tr> <tr> <td>Galapagos NV</td> <td>Rheumatoid arthritis</td> <td>US</td> <td>Phase 3 Clinical</td> <td>31-Jul-2016</td> </tr> <tr> <td>Gilead Sciences Inc</td> <td>Rheumatoid arthritis</td> <td>Europe</td> <td>Phase 3 Clinical</td> <td>31-Jul-2016</td> </tr> <tr> <td>Gilead Sciences Inc</td> <td>Rheumatoid arthritis</td> <td>US</td> <td>Phase 3 Clinical</td> <td>31-Jul-2016</td> </tr> <tr> <td>Galapagos NV</td> <td>Crohns disease</td> <td>Europe</td> <td>Phase 2 Clinical</td> <td>29-Jan-2014</td> </tr> </tbody> </table>	Company	Indication	Country	Development Status	Date	Galapagos NV	Rheumatoid arthritis	Europe	Phase 3 Clinical	31-Jul-2016	Galapagos NV	Rheumatoid arthritis	US	Phase 3 Clinical	31-Jul-2016	Gilead Sciences Inc	Rheumatoid arthritis	Europe	Phase 3 Clinical	31-Jul-2016	Gilead Sciences Inc	Rheumatoid arthritis	US	Phase 3 Clinical	31-Jul-2016	Galapagos NV	Crohns disease	Europe	Phase 2 Clinical	29-Jan-2014
Company	Indication	Country	Development Status	Date																											
Galapagos NV	Rheumatoid arthritis	Europe	Phase 3 Clinical	31-Jul-2016																											
Galapagos NV	Rheumatoid arthritis	US	Phase 3 Clinical	31-Jul-2016																											
Gilead Sciences Inc	Rheumatoid arthritis	Europe	Phase 3 Clinical	31-Jul-2016																											
Gilead Sciences Inc	Rheumatoid arthritis	US	Phase 3 Clinical	31-Jul-2016																											
Galapagos NV	Crohns disease	Europe	Phase 2 Clinical	29-Jan-2014																											
Drugs																															
Patents																															
Contract																															
Events																															
Financial																															
Mergers & Acquisition																															
Sources																															

11. **Events** 标签的内容与 Recap 的 Smart Summary 功能相似，提供该交易的综述并列重要事件、时间节点、事件类型、相关药物和付款情况。

Gilead Sciences to develop and commercialize Galapagos' filgotinib against rheumatoid arthritis and inflammatory disease worldwide

Snapshot Highlight Search Terms & Synonyms < Previous Next >

Drugs EVENTS

Patents SUMMARY

Contract

Events

- Summary
- Timeline

Financial

Mergers & Acquisition

Sources

In December 2015, Galapagos entered into an agreement with Gilead Sciences for the development and commercialization of the JAK1 selective inhibitor, filgotinib for rheumatoid arthritis and inflammatory disease worldwide. The transaction was subject to customary closing conditions and clearances under the Hart-Scott Rodino Antitrust Improvements Act [1722160]. In January 2016, Galapagos announced that the US Federal Trade Commission granted an early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Acts of 1976 (HSR Act) for the worldwide collaboration on filgotinib with Gilead Sciences and the deal was expected to close by the end of the month [1726973]. In January 2016, Galapagos and Gilead Sciences completed their global license and collaboration agreement on filgotinib against rheumatoid arthritis and inflammatory disease [1728345].

TIMELINE

Date	Event Type	Description	Drug(s)	Stage	Payment Type	Value (USD m)
19-Jan-2016	Other Deal Update	- Later in January 2016, Galapagos and Gilead Sciences completed their global license and collaboration agreement on filgotinib against rheumatoid arthritis and inflammatory disease. - The completion triggered a \$300 million upfront license fee to Galapagos, and Gilead made a \$425 million equity investment in Galapagos for new shares at a price of EUR 58 per share, including issuance premium gaining 6,760,701 ordinary shares of Galapagos [1728345]	filgotinib		Upfront Equity to Principal Company; Upfront Payment to Principal Company;	=425.00 =300.00
13-Jan-2016	Other Deal Update	- In January 2016, Galapagos announced that the US Federal Trade Commission granted an early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Acts of 1976 (HSR Act) for the worldwide collaboration on filgotinib with Gilead Sciences and the deal was expected to close by the end of the month [1726973].	filgotinib			
17-Dec-2015	Original Deal	- In December 2015, Galapagos entered into an agreement with Gilead Sciences for the development and commercialization of the JAK1 selective inhibitor filgotinib for rheumatoid arthritis and inflammatory disease worldwide.	filgotinib	Phase 2 Clinical [Notes]		

12. **Financial** 标签显示了与财务相关的具体信息，包括付款里程碑、股权信息、首付款和销售提成。还包括 projected at-signing (签订合同时的预期交易额)，projected current (目前应执行的预期交易额) 和 paid (已付金额)。点击 **Milestone** 旁边的 ‘+’，可以查看更多细节。

Gilead Sciences to develop and commercialize Galapagos' filgotinib against rheumatoid arthritis and inflammatory disease worldwide

Snapshot Highlight Search Terms & Synonyms < Previous Next >

Drugs FINANCIAL

Patents TOTAL SUMMARY (USD Millions)

Contract

Events

Financial

- Total Summary
- Principal
 - Projected At-Signing
 - Projected Current
 - Paid
- Partner
 - Projected At-Signing
 - Projected Current
 - Paid

Mergers & Acquisition

Projected At-Signing	Projected Current	Paid
2,075.00	2,075.00	725.00

PRINCIPAL

Projected At-Signing

Payment Type	Value (USD Millions)	Notes
Milestones +	1,350.00	
Equity +	425.00	
Upfront Payment	= 300.00	Upfront license fee of \$300 million.
Royalty Payment	Payment Unspecified	

Payment Type	Value (%)	Notes
Profit Split(%)	= 50.00	Profits would be shared equally.
Royalty(%)	= 20.00	Tiered royalties on global sales at 20%.

13. 如果这笔交易是合并或收购，可以点击 **Merger & Acquisition** 选项卡查看具体信息。点击表格上方的 **Back** 箭头可以返回到搜索结果页面。

Deal Report Back Forward Alert Export

Gilead Sciences to develop and commercialize Galapagos' filgotinib against rheumatoid arthritis and inflammatory disease worldwide Prev Next

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Drugs	SNAPSHOT
Patents	Deal Title: Gilead Sciences to develop and commercialize Galapagos' filgotinib against rheumatoid arthritis and inflammatory disease worldwide
Contract	Principal Company: Galapagos NV (Belgium)
Events	Partner Company: Gilead Sciences Inc (US)
Financial	Deal Type: Drug - Development/Commercialization License
Mergers & Acquisition	Deal Asset Type: Product(s) only
Sources	Deal Transaction Type: Co-Development/Co-Development Option (Shared responsibilities and costs); Co-Promotion/Co-Promotion Option (One party books sales/ shared promotion)
	Deal Status: Active
	Territories: World
	Total projected value (Current-USD M): 2075.00
	Total projected value (At Signing-USD M): 2075.00
	Total Paid (USD M): 725.00
	Indications: Colitis; Crohns disease; Rheumatoid arthritis
	Target-based Actions: Jak1 tyrosine kinase inhibitor
	Other Actions: Anti-inflammatory
	Technologies: Small molecule therapeutic(Primary); Capsule formulation; Oral formulation

14. 向右滑动结果列可以看到 **Deal Overview** 列，某些交易信息可能包含此功能。这一功能与 Recap 的 Deal Snapshot 类似，提供一张包含关键财务信息和合同条款的图片。点击可将图片放大，浏览完后再关闭该窗口。


76 results found for "rheumatoid arthritis" with filter(s) applied: Yes; Rheumatoid arthritis 1 2 3 4 5 6 7 8 Next

Results Per page: 10 Sort by: Deal Start Date Most Recent Order Columns View

Deal Title	Deal Status	Deal Overview	M&A Deal	Has Contract	Territories Included
	Filters: [0]		Filters: [0]	Filters: [0]	Filters: [0]
Dong-A to develop and commercialize Tobira's cenicriviroc in the Republic of Korea for all therapeutic indications	Active		No	Yes	South Korea
Bristol-Myers Squibb acquires Padlock Therapeutics	Completed		Yes	No	

高级检索

1. 高级检索采用“先筛选再搜索”策略，与 Recap 的检索方法类似，从检索主页右侧的 **Advanced Search** 进入。



2. 点击 **Deals** 标签进入交易检索。打开图中的下拉菜单可以看到检索项列表，一些检索项中还包含子项。例如 **Deal Type** 检索项就提供了 3 个子项。其中 **Deal Transaction Type** 中包含的具体检索条目与 Recap 中的 agreement types 非常类似。点击最右侧打开相应的具体条目列表。



3. Deal Transaction Type 中的具体检索条目。

ADVANCED SEARCH - DEAL TYPE (DEAL TRANSACTION TYPE)

Look up

Select from those listed below Finished

- Acquisition - Full (100%)
- Acquisition - Majority Stake (50-99%)
- Acquisition - Option
- Asset Purchase
- Co-Promotion Only
- Distribution
- Equity/Equity Option (<50% Stake) - Standalone
- Government Supply Contract
- Grant
- Joint Venture
- License
- Loan/Convertible Loan
- Merger
- Other Funding/Investment Vehicle
- Research-Only
- Reverse Merger
- Royalty Buyout
- Service Agreement
- Settlement
- Spin-out
- Supply Only

Selected terms 0 of 200

Cancel Clear All Apply

4. 关闭 Deal Transaction Type 窗口后，返回至高级检索主页面。现在，选择 **Indication** 检索项。

Drugs Patents Literature Clinical Trials Regulatory Deals

Enter Search Text IT

AND Title/Summary

AND Deal Type

Add an additional search criteria


Deal Finance
Deal Start Date
Technologies
Indication
Contract
Any Text

Reset SEARCH


© 2016 THOR

TERMS OF USE PRIVACY POLICY COPYRIGHT COPYRIGHT OF HEALTH AGENCIES DATA USAGE GUIDE


5. 打开右侧的检索条目列表。



6. 可以看到所有的适应症列表。




7. 输入 rheumatoid arthritis 后点击 **Look up** 检索，然后从列表中进行选择。如果适应症分属不同的治疗领域，系统会自动匹配后全部选定。如图，所有包含 rheumatoid arthritis 的治疗领域均已自动选定。然后点击 **Apply** 确认。



8. 继续添加下一个筛选项，选择 **Deal Finance**。



9. 在列表中选择 **Finance Disclosed**，查看已披露财务信息交易，点击 **Search** 开始检索。



10. 检索完成，通过高级检索功能我们能够得到与快速检索一致的结果。

在结果页面，您可以：

- a, 打开查看任意一个交易报告；
- b, 利用筛选功能进一步精炼检索结果；
- c, 导出数据供离线使用或直接分享给同事；
- d, 创建 email 提醒功能，自动提醒检索结果中的更新信息。


76 results found for ' Indication (Rheumatoid arthritis) AND Deal Finance (Finance Disclosed)'

Results Per page: 10 Sort by: Most Recent Event Date Most Recent Order Columns View

Deal Title	Principal Company	Partner Company	Deal Type	Deal Asset Type	Deal Transaction Type
Abbvie to develop and commercialize Ablynx' ALX-0081 against inflammatory diseases worldwide	Ablynx NV	Abbvie Inc	Drug - Development/Commercialization License	Product(s) only	Basic License (Licensee takes over)
NIAMD to award Navidea funding for the development of Tc-99m-tilmanocept for rheumatoid arthritis	Navidea Biopharmaceuticals Inc	National Institute of Arthritis and Musculoskeletal and Skin Diseases	Drug - Funding	Capital(Grants/Loans/Equity Inv/ Royalty buyouts)	Grant

11. 观看这个检索指南的视频版，请点击：Play recording

12. 遇到问题，请联系我们的技术支持：ts.support.china@clarivate.com



科睿唯安 (Clarivate Analytics) 简介

科睿唯安 (Clarivate Analytics) 致力于通过为全球客户提供值得信赖的数据与分析, 洞悉科技前沿、加快创新步伐, 帮助全球范围的用户更快地发现新想法、保护创新、并助力创新成果的商业化。我们提供全面的知识产权与科技信息、决策支持工具和服务为全球客户的创新生命周期提供强大助力, 帮助政府、学术界、出版商和企业在整个生命周期中: 发现新想法、保护创新, 直到最终实现商业化。我们的产品包括Web of Science™ (含科学引文索引, 即Science Citation Index, 简称SCI)、Cortellis™、Derwent Innovation™、德温特世界专利索引 (Derwent World Patents Index™, 简称DWPI)、CompuMark™、MarkMonitor® 以及Techstreet™国际标准数据库等。作为一家在全球范围独立运营的公司, 科睿唯安通过遍布世界100多个国家和地区的超过4000名员工, 一如既往地提供专业、客观、敏锐的服务。

更多信息, 请预览Clarivate.com.cn

科睿唯安生命科学事业部简介

Clarivate Analytics旗下的生命科学事业部长期以来致力于为生命科学领域的研发和创新提供强大的专业信息情报解决方案。通过专业信息数据库和深度专业服务, 我们帮助制药企业和研究单位加速药物的发现和研发、优化制药企业的知识产权组合、快速锁定授权与合作机遇及成功向监管部门注册申报, 旗下的Cortellis、Newport、Integrity等数据库已经成为国内制药企业开展药物研发、管线拓展、合作交易的重要工具。

科睿唯安为您提供

产品与解决方案

- BioWorld (生物制药行业系列资讯)
- Cortellis Clinical Trials Intelligence (全球临床试验情报数据库)
- Cortellis Competitive Intelligence (综合性竞争情报数据库)
- Cortellis Deals Intelligence (交易情报数据库)
- Cortellis Disease Briedings (疾病综述)
- Cortellis for Informatics
- Cortellis Regulatory Intelligence (全球药政法规情报数据库)
- Incidence and Prevalence Date (流行病学数据库)
- Integrity (早期研发数据库)
- Key Pathway Advisor
- MetaCore (整合性系统生物学平台)
- MetaMiner™ Program
- Newport (全球仿制药 / 原料药 / 中间体的销售、研发和专利信息数据库)
- Derwent Innovation
- Web of Science™

专业服务

- 项目 / 资产评估
- 生物信息学、统计学和疾病生物学
- 临床绩效评估
- 竞争格局分析
- 数据收集、整合与分析
- 药物再定位
- 知识产权服务
- KOL 调研
- 市场评估
- 患者分层
- Cortellis 交易支持服务
- 药政法规分析

选择科睿唯安

用于科学发现的独家数据	科睿唯安为科学发现提供最全面的整合数据, Integrity 包含药物、靶点、基因与生物标志物关联信息, MetaCore 包含高质量的系统生物学内容。
提供研发竞争格局及预测	Cortellis Competitive Intelligence 提供专业及时的新药研发管线信息, 并每日更新。包含 60,000 多种在研药物, 其中有 16,000 多种尚未进入临床研究阶段。
助力研发信息平台建立	Cortellis for Informatics 可以提供编程方式访问科睿唯安不同类型的生命科学信息内容, 适用于内部应用与网络访问。专注于研发及相关信息, 包含生物标记物、靶点、生物学通路、组学与基因变异等信息; 同时还包含全球在研新药、临床试验、竞争情报与监管指南等信息。
新靶向药物早期研发的创新工具	MetaCore、Integrity Biomarkers 与 Cortellis Clinical Trial Intelligence 等一系列创新工具可以提供基因表达数据, 助力加快新药开发, 具体包括患者分层、发病机制、作用靶点生物标志物发现, 以及药物基因组学信息等。
不可或缺的交易支持数据	无论是买入、卖出或者授权许可项目, Cortellis 交易情报都可以帮助您快速洞察关键交易趋势、发现参比同类交易与商业付费信息。我们的解决方案包含 40,000 多条交易记录, 并每日更新。
最受信赖的全球药政法规数据	Cortellis Regulatory Intelligence 收录全球最多的药政法规文件, 包含监管质量、临床前、临床、生产、申请、上市、批准后、审计 / 检查与药物安全监测等多方面内容。其中全球药政法规对比模块提供不同国家监管要求的相同与不同之处, 并提供相关摘要和原文。

更多信息请访问: Clarivate.com.cn



科睿唯安 中国办公室

北京海淀区科学院南路2号融科资讯中心C座北楼610单元
邮编: 100190
电话: +86-10 57601200
传真: +86-10 82862088
邮箱: info.china@clarivate.com
网站: clarivate.com.cn



关注我们
获取更多行业报告